Channa Kolb, MD
Neurology · Buffalo, NYNPI 1316176167
Payments from drug & device makers
Across 213 payments — averaging $481.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$44K
- EMD Serono, Inc.$20K
- AstraZeneca$18K
- Novartis$17K
- Genentech USA, Inc.$3K
- Amgen$185
- plus $633 from 13 others
What the payments were for
- Consulting fees$24,31624%
- Speaking & faculty fees$67,19066%
- Travel & lodging$5,6866%
- Food & beverage$4,9485%
- Education$3220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 47 | $43,970 |
| EMD Serono, Inc. | 42 | $20,183 |
| AstraZeneca | 22 | $17,565 |
| Novartis | 43 | $16,736 |
| Genentech USA, Inc. | 24 | $3,191 |
| Amgen | 5 | $185 |
| AbbVie | 9 | $185 |
| ANI Pharmaceuticals, Inc. | 4 | $108 |
| Sanofi | 3 | $101 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Octapharma USA, Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Tanabe Pharma America, Inc. | 1 | $25 |
| TG Therapeutics, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| UCB, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Genentech, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,463 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ajovy SyringeFremanezumab-Vfrm | 22 | $16,318 |
| Propranolol Hcl | 22 | $341 |
| Levetiracetam | 14 | $311 |
| Gabapentin | 22 | $265 |
| Donepezil Hcl | 33 | $218 |
| Sertraline Hcl | 12 | $42 |
| Memantine Hcl | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other neurology in Buffalo
- Kinga SzigetiBuffalo$3M
- Bianca Weinstock GuttmanBuffalo$1.4M
- Gil WolfeBuffalo$829K
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.